ClearPoint Neuro, Inc. (CLPT)
NASDAQ: CLPT · Real-Time Price · USD
16.72
-0.73 (-4.18%)
At close: Feb 21, 2025, 4:00 PM
16.51
-0.21 (-1.26%)
After-hours: Feb 21, 2025, 4:02 PM EST
ClearPoint Neuro Revenue
ClearPoint Neuro had revenue of $8.12M in the quarter ending September 30, 2024, with 40.96% growth. This brings the company's revenue in the last twelve months to $30.43M, up 36.34% year-over-year. In the year 2023, ClearPoint Neuro had annual revenue of $23.96M with 16.56% growth.
Revenue (ttm)
$30.43M
Revenue Growth
+36.34%
P/S Ratio
14.44
Revenue / Employee
$284,383
Employees
107
Market Cap
461.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.96M | 3.40M | 16.56% |
Dec 31, 2022 | 20.55M | 4.25M | 26.09% |
Dec 31, 2021 | 16.30M | 3.47M | 27.05% |
Dec 31, 2020 | 12.83M | 1.61M | 14.37% |
Dec 31, 2019 | 11.22M | 3.86M | 52.54% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CLPT News
- 8 days ago - ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025 - Accesswire
- 9 days ago - ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula - Accesswire
- 25 days ago - ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0 - Accesswire
- 3 months ago - ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain - Accesswire
- 3 months ago - ClearPoint Neuro: Near-Term Volatility Is No Concern - Seeking Alpha
- 3 months ago - ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - ClearPoint Neuro Reports Third Quarter 2024 Results - Accesswire
- 4 months ago - ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024 - Accesswire